ContractBoston Biomedica Inc • May 17th, 2004 • In vitro & in vivo diagnostic substances
Description of Severance Agreement provisions between Boston Biomedica, Inc. and Richard D’Allessandro, Vice President – Information Technology, contained in an internal Boston Biomedica, inc. memorandum dated March 21, 2001 between Kevin Quinlan, President and Chief Operating Officer of Boston Biomedica, Inc. and Richard D’Allessandro, Vice President, Information Technology of Boston Biomedica, Inc.:
ContractTenant Improvement Agreement • May 17th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances
THIS LEASE, Made this 1st day of March 2004, by and between MIE Properties, Inc. as agent for owner, herein called “Landlord”, and BBI Biotech Research Laboratories, Inc., herein called “Tenant”.
LEASE TERMINATION AGREEMENTLease Termination Agreement • May 17th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances
This Lease Termination Agreement (“Agreement”) is made, entered and effective this 4th day of March, 2004, by and between MANAFORT FAMILY, LLC, a limited liability company under and existing by virtue of the laws of the State of Connecticut, the successor in interest to MB Associates, having its principal place of business at 414 New Britain Avenue, Plainville, Connecticut 06062 (hereinafter referred to as “Landlord”), and Boston Biomedica, Inc., a corporation incorporated under and existing by virtue of the laws of the Commonwealth of Massachusetts, and the successor in interest to BBI-North American Clinical Laboratories, Inc., having a present principal place of business at 375 West Street West Bridgewater MA 02379 (hereinafter referred to as “Tenant”).
TERMINATION OF LEASETermination of Lease • May 17th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances
This Early Termination of Lease is made and entered into this 1st of March, 2004 by and between MIE Properties, Inc., as Landlord and BBI Biotech Research Laboratories, Inc. as Tenant.
